Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

The reserarchers found that a weekly dose of semaglutide was effective at treating Metabolic Dysfunction-Associated ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

研究人员选择研究Semaglutide作为潜在治疗方法，因为这一类药物有助于减少MASH患者的脂肪和肝脏疤痕。Newsome教授此前在《柳叶刀》和《新英格兰医学杂志》上发表的小规模积极研究表明，使用Semaglutide治疗MASH对患者有益。

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.

Results showed that 62.9% of patients on Ozempic saw a reduction in liver inflammation, compared to 34.3% on placebo.